Correction: Speaker Registration Closing Soon for Public Meeting on Clinical Trials (907)

Correction: Registration to speak at the meeting ends February 1, 2016. You can comment to the docket until April 29, 2016.  Good afternoon, The FDA Office of Minority Health (OMH) invites you to attend the Food and Drug Administration Safety and Innovation Act (FDASIA) Public Meeting: Progress on Enhancing the Collection, Analysis, and Availability of Demographic Subgroup Data. Registration to speak at the meeting ends February 1, 2016. It is very important to ensure that diverse perspectives are represented. We want to encourage you to make your voice heard and submit comments on this important topic. To make an oral presentation at the meeting, send a brief summary of your comments and registration information (name, title, firm name, address, telephone number, email address, and fax number) to FDASIA907@FDA.HHS.gov. Date:          February, 29, 2016 Time:          9 AM- 4 PM Location:   FDA White Oak Campus                  The Great Room                  10903 New Hampshire Ave                  Silver Spring, MD 20993 Register to attend the meeting by February 13, 2016 The meeting will discuss the progress the agency has made since the 2014 release of the "Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data." The report was created in response to the president signing FDASIA into law in 2012.  Section 907 of FDASIA directed FDA to publish and provide to Congress a report "addressing the extent to which clinical trial participation and the inclusion of safety and effectiveness data by demographic subgroups, including sex, age, race, and ethnicity, is included in applications submitted to FDA," among other requirements. Specifically the plan aims to:  (1) Improve quality and quantity of data derived from under-represented groups in clinical trials;  (2) Increase their participation in clinical trials; and  (3) Make data from clinical trials publicly available. Learn more about FDASIA 907 Clinical Trials Shed Light on Minority Health FDA seeks comments that (1) discuss how stakeholders have been affected by the changes implemented in the Action Plan, and (2) make recommendations for improvement.  Comment to the docket by April 29, 2016 Best Regards, Dr. Jonca Bull Assistant Commissioner for Minority Health   Visit the Office of Minority Health website or follow us @FDAOMH

 

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

 

---

This email was sent to bsamad2007.adnan@blogger.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332)